Nimotuzumab Signiifcantly Enhances Chemosensitivity of PC9 Human Lung Adenocarcinoma Cells to Paclitaxel in vitro
10.3779/j.issn.1009-3419.2015.02.09
- VernacularTitle:尼妥珠单抗对不同化疗药物在肺癌PC9细胞中敏感性的影响及其机制
- Author:
XIAO YU
1
;
CAO BAOSHAN
;
LIANG LI
Author Information
1. 北京大学第三医院肿瘤化疗与放射病科
- Keywords:
Nimotuzumab;
Paclitaxel;
Lung neoplasms;
PC9
- From:
Chinese Journal of Lung Cancer
2015;(2):98-103
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Nimotuzumab is a humanized IgG1 type monoclonal antibody targeting epidermal growth factor receptor, and can enhance chemosensitivity and radiosensitivity of certain cancers. hTe aim of this study is to investigate the effects of nimotuzumab on the chemosensitivities of PC9 human lung adenocarcinoma cells to com-mon chemtherapeutic drugs including ciaplatin, gemcitabine, paclitaxel, pemetrexed and vinorelbine, and to elucidate possible mechanisms. Methods PC9 human lung adenocarcinoma cell line was used in the study. Cell proliferation was determined by WST-1 assay and cell apoptosis was detected by TUNEL assay. Cell cycle distribution was analyzed by DNA analysis with FACS. Tublin and microiflaments were observed by immunolfuorescence staining. Results Nimotuzumab signiifcantly en-hanced the chemosensitivity of PC9 cells to paclitaxel. Cell proliferation was inhibited signiifcantly (P<0.05) and cell apoptosis rate was higher in nimotuzumab combined with low dose paclitaxel (0.05μg/mL) group (P=0.013). G2/M arrest was increased signiifcantly by nimotuzumab combined with paclitaxel group (P<0.05). Nimotuzumab caused aggregation of tublin and mi-croiflaments into well organized microtubules. Conclusion Nimotuzumab enhanced the chemosensitivity of PC9 cell to pacli-taxel by enhancing G2/M arrest and aggregation of tublin and microiflaments. hTerefore, Nimotuzumab combined with taxane drugs could be a potential effective regimen in non-small cell lung cancer.
